Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2024)
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 14 , ISSUE 2 ( July-December, 2024 ) > List of Articles

Original Article

Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study

Saba Latif, Tasnim Ahsan

Keywords : Body mass index, Diabetes mellitus, Obesity

Citation Information : Latif S, Ahsan T. Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study. Euroasian J Hepatogastroenterol 2024; 14 (2):129-133.

DOI: 10.5005/jp-journals-10018-1437

License: CC BY-NC 4.0

Published Online: 27-12-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important entity in patients with type-2 diabetes (T2D). Exploring the prevalence and related factors of MASLD is vital toward developing effective methods of diagnosis and treatment. The objective of this study was to determine the prevalence of MASLD in persons with obesity and T2D. Materials and methods: This cross-sectional study was conducted at a private healthcare facility (Medicell Clinics) in Karachi, Pakistan, reviewing records from January to December 2022. Persons of either gender aged 18 or above with a diagnosis of T2D and/or obesity were analyzed. Results: Of a total of 646 persons, 430 (66.6%) were females. The mean age was 48.58 ± 13.88 years, ranging between 18 and 85 years. T2D was noted in 351 (54.3%) patients, while obesity was observed in 593 (91.8%) persons, 396 (61.3%) had MASLD. Persons having MASLD had significantly higher body mass index (31.16 ± 5.13 vs 28.14 ± 4.76 kg/m2, p < 0.001). Likewise, obesity was significantly associated with MASLD (94.9 vs 86.8%, p < 0.001). The odds ratios (OR) and 95% confidence intervals (CIs) are reported in multivariate logistic regression table. Persons with T2DM (OR = 1.519, p = 0.009), and obesity (OR = 2.651, p = 0.001) showed significantly increased odds of having MASLD. The analysis revealed that individuals in the age-group of 18–40 (OR = 1.627, p = 0.014) had increased odds of having MASLD. Conclusion: The prevalence of MASLD was very high in persons with T2D, and obesity. Type-2 diabetes with or without obesity, or the other way around, significantly increases the risk of MASLD. Therefore, these persons should be screened for MASLD to improve clinical outcomes in the affected people.

PDF Share
  1. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res 2024;65(1):100485. DOI: 10.1016/j.jlr.2023.100485.
  2. Kanwal S, Ghaffar T, Aamir AH, et al. Frequency of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus and its associated risk factors. Pak J Med Sci 2021;37(5):1335–1341. DOI: 10.12669/pjms.37.5.4211.
  3. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr 2020;12:60. DOI: 10.1186/s13098-020-00570-y.
  4. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019;71(4):793–801. DOI: 10.1016/j.jhep.2019.06.021.
  5. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol 2014;6(5):263–273. DOI: 10.4254/wjh.v6.i5.263.
  6. Lonardo A, Ballestri S, Guaraldi G, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease – Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016;22(44):9674–9693. DOI: 10.3748/wjg.v22.i44. 9674.
  7. Loomis AK, Kabadi S, Preiss D, et al. Body mass index and risk of nonalcoholic fatty liver disease: Two electronic health record prospective studies. J Clin Endocrinol Metab 2016;101(3):945–952. DOI: 10.1210/jc.2015-3444.
  8. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73(1):202–209. DOI: 10.1016/j.jhep.2020.03.039.
  9. Seetlani NK, Memon AR, Tanveer S, et al. Frequency of non-alcoholic steatohepatitis on histopathology in patients of type 2 diabetes mellitus with duration of more than 5 Years. J Coll Physicians Surg Pak 2016;26(8):643–646. PMID: 27539754.
  10. Shah AS, Khan S, Rahim H, et al. Prevalence of non alcoholic fatty liver and non alcoholic steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan. Pak J Pharm Sci 2018;31(1):193–198. PMID: 29348103.
  11. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies [published correction appears in Lancet 2004;363(9412):902]. Lancet 2004;363(9403):157–163. DOI: 10.1016/S0140-6736(03) 15268-3.
  12. Loomba R, Wong R, Fraysse J, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: A real world analysis of Medicare data. Aliment Pharmacol Ther 2020;51(11):1149–1159. DOI: 10.1111/apt.15679.
  13. Long MT, Zhang X, Xu H, et al. Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham heart study. Hepatology 2021;73(2):548–559. DOI: 10.1002/hep.31608.
  14. Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep 2021;21(5):15. DOI: 10.1007/s11892-021-01383-7.
  15. Watt GP, De La Cerda I, Pan JJ, et al. Elevated glycated hemoglobin is associated with liver fibrosis, as assessed by elastography, in a population-based study of Mexican Americans. Hepatol Commun 2020;4(12):1793–1801. DOI: 10.1002/hep4.1603.
  16. Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14(2):99–114. DOI: 10.1038/nrendo.2017.173.
  17. Targher G, Corey KE, Byrne CD, et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18(9):599–612. DOI: 10.1038/s41575-021-00448-y.
  18. Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep 2019;1(6):468–479. DOI: 10.1016/j.jhepr.2019.10.008.
  19. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD [published correction appears in Eur Heart J 2020;41(45):4317]. Eur Heart J 2020;41(2):255–323. DOI: 10.1093/eurheartj/ehz486.
  20. Bhaskaran K, Dos-Santos-Silva I, Leon DA, et al. Association of BMI with overall and cause-specific mortality: A population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol 2018;6(12):944–953. DOI: 10.1016/S2213-8587(18)30288-2.
  21. Lonardo A, Mantovani A, Lugari S, et al. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol 2020;19(4):359–366. DOI: 10.1016/j.aohep.2020.03.001.
  22. Golabi P, Paik J, Fukui N, et al. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes 2019;37(1):65–72. DOI: 10.2337/cd18-0026.
  23. Golabi P, Paik JM, Arshad T, et al. Mortality of NAFLD according to the body composition and presence of metabolic abnormalities. Hepatol Commun 2020;4(8):1136–1148. DOI: 10.1002/hep4.1534.
  24. Ahadi M, Molooghi K, Masoudifar N, et al. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36(6):1497–1507. DOI: 10.1111/jgh.15353.
  25. Vieira Barbosa J, Lai M. Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting. Hepatol Commun 2020;5(2):158–167. DOI: 10.1002/hep4.1618.
  26. Hydes TJ, Ravi S, Loomba R, et al. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol 2020;26(4):383–400. DOI: 10.3350/cmh.2020.0067.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.